Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911431 | 1.00 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3CA12CA1 | |
| SCHEMBL29340231 | 0.81 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL911696 | 0.81 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911790 | 0.81 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL910969 | 0.81 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911791 | 0.81 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL910970 | 0.81 | SLC6A4 (0.88) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911980 | 0.80 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911981 | 0.80 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL911282 | 0.80 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| EP-1934212-A1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-06-25 | — | — | EP | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | AZI2, TPMT, TET3 | SLC6A4 1776/4885SLC6A2 1059/4885SLC6A3 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.